Since 1962, Borosil is into finest quality scientific and laboratory glassware, which is used in Quality Control in pharmaceutical industries, Food and Soil testing, Microbiology, and Biotechnology.
The company possesses a narrow moat rooted in brand equity and high switching costs within the pharmaceutical and research sectors. This is corroborated by a dominant 67% share in laboratory glassware and the high cost of re-validating primary packaging suppliers for injectable drugs, though average ROCE of 11.4% suggests the moat is not yet wide enough to generate exceptional excess returns.
Management has focused on vertical integration through the acquisition of Goel Scientific to enter process systems and the demerger to streamline the scientific business. While these moves align with long-term strategy, the current ROCE and ROE suggest that the substantial reinvestment in manufacturing and M&A has yet to yield high incremental returns.
The investment failed because management's aggressive vertical integration and M&A strategy, specifically the Goel Scientific acquisition, became a permanent drag on capital efficiency rather than a growth engine. Persistent losses in material subsidiaries and a bloated 123-day working capital cycle starved the company of liquidity, forcing a reliance on high-cost debt that eroded the once-clean balance sheet. As ROCE stagnated below the cost of capital, the market re-rated the business from a premium scientific brand to a mediocre industrial manufacturer, resulting in a permanent loss of capital.
RichFakir rates Borosil Scientific Ltd's business quality as decent — 58/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as narrow.
On our model, Borosil Scientific Ltd is trading about 33% above our estimate of fair value; we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Borosil Scientific Ltd is: Watch — wait for price. A decent business, but at an expensive price against our estimate of fair value — one to keep on the watchlist for a better entry.
RichFakir's educational estimate of Borosil Scientific Ltd's fair value is about ₹76 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →